순환종양세포 시장 보고서 : 기술별, 용도별, 제품별, 검체별, 최종사용자별, 지역별(2025-2033년)

The global circulating tumor cells (CTC) market size reached USD 12.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 27.8 Billion by 2033, exhibiting a growth rate (CAGR) of 8.46% during 2025-2033. The rising prevalence of genetic disorders, owing to lifestyle changes, is propelling the market.

Circulating tumor cells (CTC) are cancer cells that split away from the primary tumor and appear in the circulatory system as singular units or clusters. They have different biological phenotypes, such as epithelial, mesenchymal, and mixed epithelial-mesenchymal. CTC levels in a patient's blood can allow early detection of cancer and act as a prognostic indicator. As they are in minimal quantity, several technologies are used for the isolation, enrichment, and detection of CTC, such as immunocapture, size-based separation, density-based separation, and microscopy. It also has wide-ranging applications in liquid biopsy, cancer research, drug development, and clinical biomarkers.

Circulating Tumor Cells (CTC) Market Trends:

The increasing prevalence of cancer due to genetic disorders, rising alcohol consumption, and rapid lifestyle changes are key factors driving the market growth. CTC assists in the early identification and real-time monitoring of lung, breast, digestive tract, and prostate cancer. In line with this, the increasing utilization of CTC in patient screening for metastasis and preclinical studies of new cancer drugs is favoring the market growth. Furthermore, the growing demand for minimally invasive (MI) diagnostic procedures and widespread adoption of CTC-based liquid biopsy to enable rapid recovery and limit trauma are providing a considerable boost to the market growth. Apart from this, the introduction of nanotechnology to improve the sensitivity and efficiency of CTC isolation and detection is providing an impetus to market growth. Moreover, increasing utilization in medical research to develop cell culture models for drug screening, disease modeling, genome editing, and tumor immunity is creating a positive outlook for the market. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early cancer diagnosis is positively influencing the market growth. Other factors, including rapid advancements in biomedical imaging and bioengineering technology, extensive research and development (R&D) activities, and the rising demand for preventive medicine and companion diagnostics, are anticipated to drive the market growth.

Key Market Segmentation:

Breakup by Technology:

• CTC Detection and Enrichment Method
• CTC Direct Detection Methods
• CTC Analysis

Breakup by Application:

• Clinical/Liquid Biopsy
• Risk Assessment
• Screening and Monitoring
• Research
• Cancer Stem Cell and Tumorigenesis Research
• Drug/Therapy Development

Breakup by Product:

• Kits and Reagents
• Blood Collection Tubes
• Devices and Systems

Breakup by Specimen:

• Blood
• Bone Marrow
• Other Body Fluids

Breakup by End User:

• Hospital and Clinics
• Research and Academic Institutes
• Diagnostic Centres

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being BioFluidica Inc, Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc, Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V, Rarecells Diagnostics and Stemcell Technologies.

Key Questions Answered in This Report

• 1.What was the size of the global Circulating Tumor Cells (CTC) market in 2024?
• 2.What is the expected growth rate of the global Circulating Tumor Cells (CTC) market during 2025-2033?
• 3.What are the key factors driving the global Circulating Tumor Cells (CTC) market?
• 4.What has been the impact of COVID-19 on the global Circulating Tumor Cells (CTC) market?
• 5.What is the breakup of the global circulating tumor cells (CTC) market based on technology?
• 6.What is the breakup of the global Circulating Tumor Cells (CTC) market based on the application?
• 7.What is the breakup of the global Circulating Tumor Cells (CTC) market based on the product?
• 8. What is the breakup of the global Circulating Tumor Cells (CTC) market based on the specimen?
• 9.What are the key regions in the global Circulating Tumor Cells (CTC) market?
• 10.Who are the key players/companies in the global Circulating Tumor Cells (CTC) market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Circulating Tumor Cells (CTC) Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Technology

• 6.1 CTC Detection and Enrichment Method
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 CTC Direct Detection Methods
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 CTC Analysis
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Application

• 7.1 Clinical/Liquid Biopsy
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Risk Assessment
    • 7.1.2.2 Screening and Monitoring
  • 7.1.3 Market Forecast
• 7.2 Research
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Cancer Stem Cell and Tumorigenesis Research
    • 7.2.2.2 Drug/Therapy Development
  • 7.2.3 Market Forecast

8 Market Breakup by Product

• 8.1 Kits and Reagents
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Blood Collection Tubes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Devices or Systems
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Specimen

• 9.1 Blood
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Bone Marrow
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Other Body Fluids
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospital and Clinics
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Research and Academic Institutes
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Diagnostic Centres
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 BioFluidica Inc
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
  • 16.3.2 Creatv MicroTech Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 CytoLumina Technologies Corp.
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 Fluxion Biosciences Inc.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
  • 16.3.5 Greiner Bio-One International GmbH
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
  • 16.3.6 Ikonisys Inc
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
  • 16.3.7 Menarini Silicon Biosystems
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
  • 16.3.8 Miltenyi Biotec
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
  • 16.3.9 Qiagen N.V
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
  • 16.3.10 Rarecells Diagnostics
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
  • 16.3.11 Stemcell Technologies
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio